Challenges in covid vaccination in children

Dr Sheeja Sugunan Associate Professor SAT, Government Medical College Thiruvananthapuram



Globally, as of 9:17am CEST, 13 October 2021, there have been 238,229,951 confirmed cases of COVID-19, including 4,859,277 deaths, reported to WHO. As of 9 October 2021, a total of 6,364,021,792 vaccine doses have been administered.

COVID Vaccination Worldwide



Share of the population fully vaccinated against COVID-19, Oct 12, 2021 Total number of people who received all doses prescribed by the vaccination protocol, divided by the total population of the country.



Oct 12, 2021

World \sim UAF 87% India 21.6% Congo <0.1% 10% 20% No data 0% 30% 40% 50% 60% 70% 80% 90%


Source: Official data collated by Our World in Data – Last updated 13 October 2021, 12:30 (London time) Our WorldInData.org/coronavirus • CC BY Note: Alternative definitions of a full vaccination, e.g. having been infected with SARS-CoV-2 and having 1 dose of a 2-dose protocol, are ignored to maximize comparability between countries.




Vaccination in children



Vaccine effectiveness in *hospitalization* due to **Delta** covishield Vs Pfizer



Vaccine efficacy : wks post vaccination Astra zenacea



Nick Andrews1,2, Elise Tessier1, Julia Stowe1Vaccine effectiveness and duration of protection of Comirnaty, Vaxzevria and Spikevax against mild and severe COVID-19 in the UK (pre print)

Breakthrough infections in vaccinated Jan – April 2021


- 101million vaccinated
- 10262 breakthrough infections
- Median age 58 yrs (40-74)
- 88% asymptomatic / MILD

COVID-19 Vaccine Breakthrough Infections Reported to CDC — United States, January 1–April 30, 2021. MMWR Morb Mortal Wkly Rep 2021;70:792–793.

Death in breakthrough cases

- 2% died due to breakthrough infections
- Median age 82years(IQR 70 -89)]
- 18% of deaths occurred in asymptomatic or due to other disease.
- 5% sequenced
- 64% were SARS COV2 variants of concern.

Massachusetts, July 2021




Specimen collection date, July

In high exposure gatherings...

- July 3 Massachusetts, reported 0 cases in the preceding two weeks.
- 69% of population in Massachusetts, fully vaccinated.
- July(3-17) 2021 469 cases occurred from public gathering.
- ³/₄(74%) in fully vaccinated. Median age 42 yrs
- 90% Delta variant.
- 70% symptomatic, 4 hospitalization, No death.


Brown CM, Vostok J, Johnson H, et al. Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021. MMWR Morb Mortal Wkly Rep 2021;70:1059-1062. DOI: RT-PCR Ct values in vaccinated patients were similar to those among unvaccinated, not fully vaccinated



Brown CM, Vostok J, Johnson H, et al. Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021. MMWR


Viral load


- Same in children and adults
- Same in symptomatic and asymptomatic in children



Madera, S., Crawford, E., Langelier, C. *et al.* Nasopharyngeal SARS-CoV-2 viral loads in young children do not differ significantly from those in older children and adults. *Sci Rep* **11**, 3044 (2021). https://doi.org/10.1038/s41598-021-81934-w

Live virus neutralizing Antibody





CDC recommendations for booster shots Oct 2021, 0,1,6mo

- 65 years and older
- Age 18+ who live in <u>long-term care settings</u>
- Age 18+ who have <u>underlying medical conditions</u>
- Age 18+ who work in <u>high-risk settings</u>
- Age 18+ who live in <u>high-risk settings</u>

Workers who may get Pfizer-BioNTech booster shots (CDC Oct 2021)

- First responders (e.g., healthcare workers, firefighters, police, congregate care staff)
- Education staff (e.g., teachers, support staff, daycare workers)
- Food and agriculture workers
- Manufacturing workers
- Corrections workers
- U.S. Postal Service workers
- Public transit workers
- Grocery store workers


Vaccine efficacy in adults

- Vaccines does not produce sterilizing immunity.
- Breakthrough infection with newer strains high
- Waning effectiveness of vaccines beyond 5 -8 months
- Lot more research is needed vaccine kinetics
- Chance of hospitalization and death significantly less in vaccinated


VACCINE MAINLY EFFECTIVE AGAINST DEATH AND HOSPITALISATION

MMRWR august 2021, new covid cases and hospitalisations amog adults by vaccination status may3 –July 25, 2021


Need of COVID vaccine in children



UK post school opening sep 2021 weighted prevalence (REACT 1study)





Incidence rate ratios (IRRs) and test positivity rate ratios (RRs) after school opening



Somekh I, Boker LK, Shohat T, Pettoello-Mantovani M, Simões EAF, Somekh E. Comparison of COVID-19 Incidence Rates Before and After School Reopening in Israel. JAMA Netw Open. 2021;4(4):e217105. doi:10.1001/jamanetworkopen.2021.7105

Children were less likely to be the source for SARS-CoV-2 infection within households, while opening educational facilities did not change transmission dynamics.






- COVID 19 mortality more in males
- Exponential increase of COVID-19-related mortality with age.
- Increase in age of 10 years increased mortality by *a factor* of around 4

Bauer, P., Brugger, J., König, F. et al. An international comparison of age and sex dependency of COVID-19 deaths in 2020: a descriptive analysis. Sci Rep **11**, 19143 (2021). https://doi.org/10.1038/s41598-021-97711-8


Age distribution among COVID 19 deaths

US Kerala




Technical paper COVID 19 DEATHS Department of Health & Family Welfare Government of Kerala [18th June to 3rd Sept 2021]

Age distribution among COVID 19 deaths




Technical paper COVID 19 DEATHS Department of Health & Family Welfare Government of Kerala [18th June to 3rd Sept 2021]

Age group and mortality (<18yrs) (All cause Vs COVID 19)



C Smith, D Odd, R Harwood, J Ward, M Linney, Deaths in Children and Young People in England following SARS-CoV-2 infection during the first pandemic year: a national study using linked mandatory child death reporting data.


Ethnic group and mortality (<18yrs) (All cause Vs COVID 19)



All deaths SARS-CoV-2 contributed to death

C Smith, D Odd, R Harwood, J Ward, M Linney, Deaths in Children and Young People in England following SARS-CoV-2 infection during the first pandemic year: a national study using linked mandatory child death reporting data.

COVID 19 in hospitalized Children





Ben-Shimol S, Livni G, Megged O, Greenberg D, Danino et al COVID-19 in a Subset of Hospitalized Children in Israel. J Pediatric Infect Dis Soc. 2021 Aug 17;10(7):757-765. doi: 10.1093/jpids/piab035. PMID: 34129032;

Deaths in Children and Young People in England following SARS-CoV-2 infection during the first pandemic year: a national study using linked mandatory child death reporting data

C Smith, D Odd, R Harwood, J Ward, M Linney, M Clark, D Hargreaves, SN Ladhani, E Draper, PJ Davis, SE Kenny, E Whittaker, K Luyt, RM Viner, LK F raser **doi:** https://doi.org/10.1101/2021.07.07.2125977

- March 2020 to feb 2021 (total death aprox 80,000)
- 61 deaths were covid positive (5 deaths every 30 days) <18yrs
- 25 died due to COVID 19 (22 due to acute disease and 3 due to MIS-C)
- 3044 died due to other causes (250 deaths every 30 days)
- Case fatality rate 0.005% (5 per 100,000)

COVID mortality in children

- 76% of COVID deaths in children had comorbidities (74% in all cause death).
- 60% had a life limiting comorbidity
- Neurological comorbidity was the commonest (52%)
- No death in trisomy, asthma, Ty I DM, Epilepsy (UK)
- Absolute risk of death even in those with life threatening neurodisability was less. (88.9 per 100,000 (95%CI 47.3-152) compared to 2,441 per 100,000 (95% CI 2,194-2,707) with life-limiting neurodisability who died of all other causes.)

C Smith, D Odd, R Harwood, J Ward, M Linney Deaths in Children and Young People in England following SARS-CoV-2 infection during the first pandemic year: a national study using linked mandatory child death reporting data

Long COVID in children

- Headache, fatigue, disturbed sleep, problems concentrating
- 2-4% of 1734 covid positive children in UK.
- 11% of 13,864 children aged three to 18yrs in Israel.
- PCR proven 11 17 year old in UK 3065 Vs 3739 (matched cohort): 14% have persistent symptoms 15 weeks after testing positive.

Stephenson T, Pereira S, Shafran R, et al Long covid—the physical and mental health of children and non-hospitalised young people 3 months after SARS-CoV-2 infection; a national matched cohort study (The CLoCk) Study.2021. doi:10.21203/rs.3.rs-798316/v1


Need

- Covid mortality extremely rare (CFR 0.005 0.008).
- School reopening has increased cases in children but no exponential increase in adults
- Children as a primary source of infection in household only in 2 9%
- 2 -11% of children have long covid
- Increase in infection and admission with covid post school opening.
- Breakthrough infection India 10% , CFR 0.4%


Gupta N, Kaur H, Yadav PD, Mukhopadhyay L, Sahay RR, Clinical Characterization and Genomic Analysis of Samples from COVID-19 Breakthrough Infections during the Second Wave among the Various States of India. Viruses. 2021 Sep 7;13(9):1782.

COVID vaccine: How safe?

Vaccines and rare side effects



Post vaccination Myocarditis (cases /million)



Gargano JW, Wallace M, Hadler SC, et al. Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021. MMWR Morb Mortal Wkly Rep 2021;70:977–982.

Covid 19 vaccine and myocarditis

- Cases reported following m RNA vaccine
- Onset of symptoms median 3 days (range 0 179days)
- Median duration of admission 2 days (IQR2-3days)
- No deaths reported

Diaz GA, Parsons GT, Gering SK, Meier AR, Hutchinson IV, Robicsek A. Myocarditis and Pericarditis After Vaccination for COVID-19. JAMA. Published online August 04, 2021. doi:10.1001/jama.2021.13443

Myocarditis and COVID Vaccine (Pfizer BioNtech)

- Among 2.5 million vaccinated HCO
- 2.13 cases per 100,000 vaccinated (>16yrears)
- CDC 3.8/ 1million 1st dose, 57 per 1 million for 2nd dose
- Highest incidence 16 -29years
- In 16 -29 yr group ,10.69 cases per 100,000 persons (95% CI, 6.93 to 14.46)

Guy Witberg, Noam Barda,Sara Hoss et al Myocarditis after Covid-19 Vaccination in a Large Health Care Organization October 6, 2021DOI: 10.1056/NEJMoa2110737 ISRAEL

Myocarditis and COVID Vaccine (Pfizer BioNtech)

- 71% LV function normal at admission
- 76% mild, 22% moderate only 1 case cardiogenic shock
- Follow up echocardiography at day 25(median) was normal in all (5 cases results not available)

Guy Witberg, Noam Barda,Sara Hoss et al Myocarditis after Covid-19 Vaccination in a Large Health Care Organization October 6, 2021DOI: 10.1056/NEJMoa2110737 ISRAEL


COVID 19 infection and myocarditis

- 1597 US competitive collegiate athletes
- 2.3% had myocarditis (9 clinical and 28 subclinical)
- Follow-up CMR imaging performed in 27 (73.0%) demonstrated resolution of T2 elevation in all (100%) and late gadolinium enhancement in 11 (40.7%).

Daniels CJ, Rajpal S, Greenshields JT, et al. Prevalence of Clinical and Subclinical Myocarditis in Competitive Athletes With Recent SARS-CoV-2 Infection: Results From the Big Ten COVID-19 Cardiac Registry. *JAMA Cardiol.* Published online May 27, 2021. doi:10.1001/jamacardio.2021.2065

Pfizer study 5 -11years GMT 1 month after 2 dose

United States, Finland, Poland, and Spain from more than 90 clinical trial sites. Under 5: 3mcg



GMT



Plasmid DNA vaccine (Zycov-d)

- Worlds first human plasmid DNA vaccine.
- Approved for those above 12 years
- They are more stable (3mo at 25C)
- Needle free intradermal injection.
- 67% efficacy with three dose schedule

Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in IndiaMomin, Taufik et al.EClinicalMedicine, Volume 38,

Zycov D safety and efficacy

- Dey A, Chozhavel Rajanathan Tmet al Immunogenic potential of DNA vaccine candidate, ZyCoV-D against SARS-CoV-2 in animal models. Vaccine. 2021 Jul Epub 2021 Jun 1.
- Momin, Taufik et al. Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India EClinicalMedicine, Volume 38, July 2021
- *Phase III* 28,216 subjects enrolled . Study yet to be published!! 67% efficacy
- No DNA vaccine currenty in use in humans



- Killed vaccine, 2 doses 1 month apart
- Used in India, Bangladesh, Myanmar, Nepal, Bhutan, Maldives, Mauritius, Seychelles, Brazil, Morocco, South Africa.
- Phase 3 trials 24,419 subjects 78% efficacy against symptomatic covid.

_Raches Ella, Siddarth Reddy, William Blackwelder, Varsha Potdar, Pragya Yadav et al Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a, double-blind, randomised, controlled phase 3 trial pre print

COVAXIN


٠

- Expert recommendation for those > 2 years
- Study done in 1000 subjects.
- More breakthrough infection with COVAXIN .
- Not yet approved by WHO for adults.
- Lower antibody titer can it lead to antibody mediated enhancement in future not known.

Safety of covid vaccines in children

- Children are not small adults.
- Their immune system responds differently to vaccines compared to adult.
- Longer life period ahead also may be at higher risk of 1st antigen sin.
- Studies of Indian vaccines phase 3 not yet published.
- Indian vaccines authorized for use in children not yet approved by WHO.

Children if being vaccinated for adults it needs to be very safe : robust study & data transparency



To protect children




Urgent need for more long term safety n Immunogenicity data.




 Anderson M, Stec M, Rewane A, Landay A, Cloherty G, Moy J. SARS-CoV-2 Antibody Responses in Infection-Naive or Previously Infected Individuals After 1 and 2 Doses of the BNT162b2 Vaccine. JAMA Netw Open. 2021;4(8):e2119741. doi:10.1001/jamanetworkopen.2021.19741

• Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science 2021;371(6529):eabf4063-eabf4063. Vaccines do not provide full (100%) protection, so breakthrough infections can happen.




Time trend case fatality rate Kerala



Time trend analysis of CFR clearly demonstrates that compared to the peak of second wave surge, CFR has gradually come down with time.

Mortality in < 18 years



C Smith, D Odd, R Harwood, J Ward, M Linney Deaths in Children and Young People in England following SARS-CoV-2 infection during the first pandemic year: a national study using linked mandatory child death reporting data

School opening and covid 19

- Israel : 54% 12 -15 yrs and 84% 16 -19yrs vaccinated, less than 12yrs those with comorbidities.
- Israel opened school in Sep.: 54% of positive tests were in children.
- In Israel 0.2 0.5% of ICU admission < 18 years (October 2021)

COVID and mortality in children

- Case fatality rate extremely low (0.005%)
- 75 90% have comorbidity .
- Higher incidence in those with neurological life limiting comobidities.
- Even in those with comorbidities risk of death due to covid per se is very rare



Covid vaccine: India drones deliver Covid jabs to remote areas



- 100Cr doses
- 22% fully vaccinated
- 52% 1 dose

Efficacy in adults covid vaccine

- Vaccine efficacy against infection declined from 91.7% to 79.8% (post delta)
- Waning humoral immunity after 24 weeks (booster at 8months) especially , > 65 yrs, immunocompromised.
- Vaccine efficacy for hospitalization >90% for mRNA vaccines
- 63% effective against hospitalizations in immunocompromised

MMRWR august 2021, new covid cases and hospitalisations amog adults by vaccination status may3 –July 25, 2021